1889 related articles for article (PubMed ID: 27235391)
1. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
3. DNA Vaccines to Improve Immunogenicity and Effectiveness in Cancer Vaccinations: Advancement and Developments.
Singh AK; Malviya R
Curr Gene Ther; 2023; 23(3):170-183. PubMed ID: 36537599
[TBL] [Abstract][Full Text] [Related]
4. Specific immunotherapy of cancer in elderly patients.
Matzku S; Zöller M
Drugs Aging; 2001; 18(9):639-64. PubMed ID: 11599633
[TBL] [Abstract][Full Text] [Related]
5. IL-13 receptor-directed cancer vaccines and immunotherapy.
Nakashima H; Husain SR; Puri RK
Immunotherapy; 2012 Apr; 4(4):443-51. PubMed ID: 22512637
[TBL] [Abstract][Full Text] [Related]
6. An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.
Jones RF; Reyes JD; Gibson HM; Jacob JB; Vaishampayan U; Ratner S; Chen K; Wei WZ
Cancer Immunol Immunother; 2019 Jul; 68(7):1143-1155. PubMed ID: 31177328
[TBL] [Abstract][Full Text] [Related]
7. Methods for improving the immunogenicity and efficacy of cancer vaccines.
Pilla L; Ferrone S; Maccalli C
Expert Opin Biol Ther; 2018 Jul; 18(7):765-784. PubMed ID: 29874943
[TBL] [Abstract][Full Text] [Related]
8. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
9. At the bench: Engineering the next generation of cancer vaccines.
Shae D; Baljon JJ; Wehbe M; Becker KW; Sheehy TL; Wilson JT
J Leukoc Biol; 2020 Oct; 108(4):1435-1453. PubMed ID: 31430398
[TBL] [Abstract][Full Text] [Related]
10. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccines for cancer.
Shaw DR; Strong TV
Front Biosci; 2006 Jan; 11():1189-98. PubMed ID: 16146806
[TBL] [Abstract][Full Text] [Related]
12. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
13. Personalized cancer vaccines: adjuvants are important, too.
Gouttefangeas C; Rammensee HG
Cancer Immunol Immunother; 2018 Dec; 67(12):1911-1918. PubMed ID: 29644387
[TBL] [Abstract][Full Text] [Related]
14. Recombinant
Deng W; Lira V; Hudson TE; Lemmens EE; Hanson WG; Flores R; Barajas G; Katibah GE; Desbien AL; Lauer P; Leong ML; Portnoy DA; Dubensky TW
Proc Natl Acad Sci U S A; 2018 Aug; 115(32):8179-8184. PubMed ID: 30038013
[TBL] [Abstract][Full Text] [Related]
15. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.
Zhang H; Wang Y; Liu C; Zhang L; Xia Q; Zhang Y; Wu J; Jiang C; Chen Y; Wu Y; Zha X; Yu X; Kong W
Cancer Immunol Immunother; 2012 Oct; 61(10):1857-67. PubMed ID: 22706381
[TBL] [Abstract][Full Text] [Related]
16. Use of adjuvants for immunotherapy.
Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
[TBL] [Abstract][Full Text] [Related]
17. Antigen-specific vaccines for cancer treatment.
Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
[TBL] [Abstract][Full Text] [Related]
18. A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy.
Duperret EK; Liu S; Paik M; Trautz A; Stoltz R; Liu X; Ze K; Perales-Puchalt A; Reed C; Yan J; Xu X; Weiner DB
Clin Cancer Res; 2018 Dec; 24(23):6015-6027. PubMed ID: 30262507
[TBL] [Abstract][Full Text] [Related]
19. Cancer Vaccines, Adjuvants, and Delivery Systems.
Paston SJ; Brentville VA; Symonds P; Durrant LG
Front Immunol; 2021; 12():627932. PubMed ID: 33859638
[TBL] [Abstract][Full Text] [Related]
20. [NY-ESO-1 and cancer immunotherapy].
Peng JR; Leng XS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
